Key Highlights
- Net loss narrowed to USD 1.5 million from USD 1.9 million.
- Loss per share was USD 0.62, against an estimated USD 0.72.
- Research and development expense was about USD 733 thousand.
- Cash and equivalents were about USD 2.8 million at September 30.
In September 2026 the first patient received a dose in the Phase 2a trial of Nu-3, which the company called an important clinical development milestone. Nu-3 is a gel applied to the skin to fight infection in diabetic foot ulcers that are mildly infected. Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) develops a class of fast-acting, broad-spectrum antimicrobials called Bisphosphocins, aimed at infections that include those caused by resistant pathogens.
Commercial product sales have produced no Revenue so far, and spending on research, development and administration is expected to stay high now that the company is public. The work covers research, running clinical trials, manufacturing, planning for regulators and protecting intellectual property.
Quarterly Spending and the Loss
The third-quarter 2026 net loss was USD 1,474,731 versus USD 1,907,159. Per share, the loss was USD 0.62 versus USD 3.46, against an estimated loss of USD 0.72. Operating expenses fell 20% to USD 1,510,731 from USD 1,880,317.
Research and development expense dipped 3% to about USD 733 thousand from about USD 753 thousand. Clinical and pre-clinical costs rose to USD 451,811 from USD 32,933, but lower personnel costs offset them. General and administrative expense fell 31% to about USD 776 thousand. Personnel costs there were down about USD 494 thousand, while corporate expenses, including insurance and investor relations, were up about USD 158 thousand. The company also held about USD 0.5 million of certificates of deposit with maturities of more than 90 days and less than a year, carried at amortized cost.
Nine Months and Liquidity
Over nine months, the net loss was USD 6,170,030 versus USD 3,102,719, or USD 4.50 per share versus USD 6.61. Operating expenses were USD 6,187,142 versus USD 3,060,310, reflecting continued clinical development spending. Net loss attributable to common stockholders was USD 6,789,258 versus USD 4,598,729. A one-for-ten reverse stock split, effective June 19, 2026, is built into the per-share numbers.
Research and development expense for the period rose to about USD 4.8 million, an increase of about USD 2.8 million, or 140%, and general and administrative expense grew about 33% to about USD 1.4 million. Investing activities used about USD 0.5 million, against none in the prior-year period.
Cash and cash equivalents were about USD 2.8 million, alongside USD 0.5 million of certificates of deposit and Working Capital of about USD 2.8 million. At year-end the figures were USD 236 thousand of cash and a working capital Deficit of about USD 2.1 million. The change is owed to Series C convertible preferred financing, which raised net proceeds of about USD 6.8 million, and to earlier preferred stock and notes converting when the company listed on Nasdaq. Total Assets were USD 3,598,419 versus USD 481,598 at year-end.
Series C Redemption and Points to Follow
After the quarter ended, the company agreed to redeem all 127,097 remaining Series C Preferred Shares for USD 1,270,970, a step it said eliminates the overhang from conversions at a variable price. The company says more financing will be needed to carry the clinical programs. Trial enrollment for Nu-3, the cash balance once the redemption is paid and administrative and research spending are what to follow.




_11_19_2026_19_57_40_035532.jpg)

Please wait processing your request...